Get started
Author

Anup Choudhury

Observed names: A. Choudhury, Choudhury, Anup
Institution: Novartis (India)
ORCID: 0000-0003-0813-6036
Observed ORCID: 0000-0003-0813-6036
OpenAlex ID: A5028027376
Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-Induced Osteoporosis: A Randomized, Double-Blind, Phase 3 Trial
2021 · Leanne M Ward, Anup Choudhury, et al. · The Journal of Clinical Endocrinology & Metabolism · 38
PDF
Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries
2020 · Katrine Hass Rubin, Sören Möller, et al. · Bone · 21
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)
2024 · A. Fernandez-Martinez, M. Tanioka, et al. · Annals of Oncology · 4
PDF
From lab-to-clinic with model informed formulation development: a case study of hydroxyzine SR tablets
2025 · Aditya Murthy, Shubham Jamdade, et al. · Xenobiotica · 1
Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial
2019 · Leanne M Ward, Nathalie Alos, et al. · Bone Abstracts · 1
Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)]
2026 · Maria Carmen De Santis, Christine Campbell, et al. · EClinicalMedicine
Rare Special Breast Cancer Histologies in the ALTTO Trial: Central Histology Review and Outcomes
2026 · Riccardo Gerosa, Guilherme Nader-Marta, et al. · Research Square
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial
2025 · Christian F. Singer, Franz Koenig, et al. · The Breast
PDF
Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]).
2025 · Guilherme Nader Marta, Lieveke Ameye, et al. · Journal of Clinical Oncology
Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.
2022 · Carmine De Angelis, Jamunarani Veeraraghavan, et al. · Journal of Clinical Oncology
Safety pharmacovigilance of biologicals and differences from small molecules
2017 · Anup Choudhury · Journal of Pharmacovigilance
Works count: 12
Citation count: 65
H-index: 3
I10-index: 2
Year
Topic
Type